Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Hold at TD Cowen

Keros Therapeutics (NASDAQ:KROS) was downgraded by TD Cowen from a “buy” rating to a “hold” rating in a report released on Thursday, MarketBeat Ratings reports.

Several other research analysts also recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday. Guggenheim reissued a “buy” rating and issued a $102.00 target price (up from $96.00) on shares of Keros Therapeutics in a research report on Wednesday, December 4th. Finally, Bank of America dropped their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $18.83 on Thursday. Keros Therapeutics has a one year low of $15.67 and a one year high of $73.00. The company has a market cap of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20. The business has a fifty day moving average of $59.11 and a two-hundred day moving average of $52.63.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same period last year, the business earned ($1.33) EPS. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. Sell-side analysts predict that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC boosted its holdings in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after acquiring an additional 298,694 shares during the period. Darwin Global Management Ltd. grew its position in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. grew its position in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP raised its stake in shares of Keros Therapeutics by 22.5% during the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock valued at $48,959,000 after purchasing an additional 154,784 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.